Antiviral immunity following smallpox virus infection

A case-control study

Erika Hammarlund, Matthew W. Lewis, Jon Hanifin, Motomi (Tomi) Mori, Caroline W. Koudelka, Mark Slifka

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Outbreaks of smallpox (i.e., caused by variola virus) resulted in up to 30% mortality, but those who survived smallpox infection were regarded as immune for life. Early studies described the levels of neutralizing antibodies induced after infection, but smallpox was eradicated before contemporary methods for quantifying T-cell memory were developed. To better understand the levels and duration of immunity after smallpox infection, we performed a case-control study comparing antiviral CD4+ and CD8+ T-cell responses and neutralizing antibody levels of 24 smallpox survivors with the antiviral immunity observed in 60 smallpox-vaccinated (i.e., vaccinia virus-immune) control subjects. We found that the duration of immunity following smallpox infection was remarkably similar to that observed after smallpox vaccination, with antiviral T-cell responses that declined slowly over time and antiviral antibody responses that remained stable for decades after recovery from infection. These results indicate that severe, potentially life-threatening disease is not required for the development of sustainable long-term immunity. This study shows that the levels of immunity induced following smallpox vaccination are comparable in magnitude to that achieved through natural variola virus infection, and this may explain the notable success of vaccination in eradicating smallpox, one of the world's most lethal diseases.

Original languageEnglish (US)
Pages (from-to)12754-12760
Number of pages7
JournalJournal of Virology
Volume84
Issue number24
DOIs
StatePublished - Dec 2010

Fingerprint

Variola virus
Smallpox
Virus Diseases
case-control studies
Antiviral Agents
Case-Control Studies
Immunity
immunity
infection
T-lymphocytes
vaccination
neutralizing antibodies
Infection
Vaccination
Vaccinia virus
Neutralizing Antibodies
T-Lymphocytes
duration
sustainable development
Conservation of Natural Resources

ASJC Scopus subject areas

  • Immunology
  • Virology

Cite this

Antiviral immunity following smallpox virus infection : A case-control study. / Hammarlund, Erika; Lewis, Matthew W.; Hanifin, Jon; Mori, Motomi (Tomi); Koudelka, Caroline W.; Slifka, Mark.

In: Journal of Virology, Vol. 84, No. 24, 12.2010, p. 12754-12760.

Research output: Contribution to journalArticle

Hammarlund, Erika ; Lewis, Matthew W. ; Hanifin, Jon ; Mori, Motomi (Tomi) ; Koudelka, Caroline W. ; Slifka, Mark. / Antiviral immunity following smallpox virus infection : A case-control study. In: Journal of Virology. 2010 ; Vol. 84, No. 24. pp. 12754-12760.
@article{38837d230897426ab4c43d8275b18c55,
title = "Antiviral immunity following smallpox virus infection: A case-control study",
abstract = "Outbreaks of smallpox (i.e., caused by variola virus) resulted in up to 30{\%} mortality, but those who survived smallpox infection were regarded as immune for life. Early studies described the levels of neutralizing antibodies induced after infection, but smallpox was eradicated before contemporary methods for quantifying T-cell memory were developed. To better understand the levels and duration of immunity after smallpox infection, we performed a case-control study comparing antiviral CD4+ and CD8+ T-cell responses and neutralizing antibody levels of 24 smallpox survivors with the antiviral immunity observed in 60 smallpox-vaccinated (i.e., vaccinia virus-immune) control subjects. We found that the duration of immunity following smallpox infection was remarkably similar to that observed after smallpox vaccination, with antiviral T-cell responses that declined slowly over time and antiviral antibody responses that remained stable for decades after recovery from infection. These results indicate that severe, potentially life-threatening disease is not required for the development of sustainable long-term immunity. This study shows that the levels of immunity induced following smallpox vaccination are comparable in magnitude to that achieved through natural variola virus infection, and this may explain the notable success of vaccination in eradicating smallpox, one of the world's most lethal diseases.",
author = "Erika Hammarlund and Lewis, {Matthew W.} and Jon Hanifin and Mori, {Motomi (Tomi)} and Koudelka, {Caroline W.} and Mark Slifka",
year = "2010",
month = "12",
doi = "10.1128/JVI.01763-10",
language = "English (US)",
volume = "84",
pages = "12754--12760",
journal = "Journal of Virology",
issn = "0022-538X",
publisher = "American Society for Microbiology",
number = "24",

}

TY - JOUR

T1 - Antiviral immunity following smallpox virus infection

T2 - A case-control study

AU - Hammarlund, Erika

AU - Lewis, Matthew W.

AU - Hanifin, Jon

AU - Mori, Motomi (Tomi)

AU - Koudelka, Caroline W.

AU - Slifka, Mark

PY - 2010/12

Y1 - 2010/12

N2 - Outbreaks of smallpox (i.e., caused by variola virus) resulted in up to 30% mortality, but those who survived smallpox infection were regarded as immune for life. Early studies described the levels of neutralizing antibodies induced after infection, but smallpox was eradicated before contemporary methods for quantifying T-cell memory were developed. To better understand the levels and duration of immunity after smallpox infection, we performed a case-control study comparing antiviral CD4+ and CD8+ T-cell responses and neutralizing antibody levels of 24 smallpox survivors with the antiviral immunity observed in 60 smallpox-vaccinated (i.e., vaccinia virus-immune) control subjects. We found that the duration of immunity following smallpox infection was remarkably similar to that observed after smallpox vaccination, with antiviral T-cell responses that declined slowly over time and antiviral antibody responses that remained stable for decades after recovery from infection. These results indicate that severe, potentially life-threatening disease is not required for the development of sustainable long-term immunity. This study shows that the levels of immunity induced following smallpox vaccination are comparable in magnitude to that achieved through natural variola virus infection, and this may explain the notable success of vaccination in eradicating smallpox, one of the world's most lethal diseases.

AB - Outbreaks of smallpox (i.e., caused by variola virus) resulted in up to 30% mortality, but those who survived smallpox infection were regarded as immune for life. Early studies described the levels of neutralizing antibodies induced after infection, but smallpox was eradicated before contemporary methods for quantifying T-cell memory were developed. To better understand the levels and duration of immunity after smallpox infection, we performed a case-control study comparing antiviral CD4+ and CD8+ T-cell responses and neutralizing antibody levels of 24 smallpox survivors with the antiviral immunity observed in 60 smallpox-vaccinated (i.e., vaccinia virus-immune) control subjects. We found that the duration of immunity following smallpox infection was remarkably similar to that observed after smallpox vaccination, with antiviral T-cell responses that declined slowly over time and antiviral antibody responses that remained stable for decades after recovery from infection. These results indicate that severe, potentially life-threatening disease is not required for the development of sustainable long-term immunity. This study shows that the levels of immunity induced following smallpox vaccination are comparable in magnitude to that achieved through natural variola virus infection, and this may explain the notable success of vaccination in eradicating smallpox, one of the world's most lethal diseases.

UR - http://www.scopus.com/inward/record.url?scp=78649398831&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78649398831&partnerID=8YFLogxK

U2 - 10.1128/JVI.01763-10

DO - 10.1128/JVI.01763-10

M3 - Article

VL - 84

SP - 12754

EP - 12760

JO - Journal of Virology

JF - Journal of Virology

SN - 0022-538X

IS - 24

ER -